🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Cannabis Investing News: Why CHC & ACB Stock Climbed Today

Published 01/14/2019, 06:29 AM
Updated 07/09/2023, 06:31 AM
SO
-
WEED
-
TLAA
-
ACB
-

Cannabis investors saw a pair of notable moves in popular stocks on Monday, with Canopy Growth (NYSE:CGC) moving 11% and Aurora Cannabis (TO:ACB) adding nearly 7% on the back of exciting deals for both companies.

Canopy Growth on Monday received a license from New York that will allow the Canadian company to process and produce hemp in the state. The move is a part of larger efforts from New York Governor Andrew Cuomo and U.S. Senator Charles Schumer as well as Canopy’s own hopes to break into the U.S. market.

In a company press release, Canopy cited Cuomo’s help in creating the Hemp Research Pilot Program and Schumer’s leadership in passing the recent U.S. farm bill as being instrumental in getting the deal done. The 2018 edition of the farm bill legalized the production of hemp in the United States.

A final location for Canopy Growth’s New York site will depend on a board vote, but the company is currently evaluating a number of spots in the Southern (NYSE:SO) Tier of the state, according to CNBC. Canopy plans to invest up to $150 million in the location, which it hopes will be “capable of producing tons of hemp” annually.

Schumer’s office added in its own release that the company’s investment “is a true win-win for Canopy Growth, who will be positioned at the forefront of Upstate New York's industrial hemp revolution, and for the Southern Tier's economy and farmers, which will receive a major shot in the arm in new good-paying jobs.”

Meanwhile, fellow Canadian marijuana producer Aurora Cannabis announced Monday that it is acquiring British Columbia-based Whistler Medical Marijuana for about $132 million. Whistler is a recognizable brand in Canada and received one of the country’s original 10 licenses to produce marijuana. It was also the first marijuana company to earn organic certification in Canada.

“This transaction adds an iconic, organic certified BC-based brand with exceptional traction and a significant price premium in both the medical and retail markets,” said Aurora CEO Terry Booth.

On top of its recognizability, Whistler offers Aurora a unique opportunity to expand internationally, as it already sells medical cannabis derivatives to Australia and the Cayman Islands. Whistler’s second production facility is expected to be completed this summer and will have a capacity of over 5,000 kilograms per year.

Canopy Growth and Aurora’s deal-making spread optimism to the rest of the marijuana industry during the week’s first trading session. The ETFMG Alternative Harvest ETF (SNX:MJ) gained 1.7% on Monday, underscoring hopes for more major deals that can add legitimacy to the young business.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.